Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Breast Neoplasms × alpha-Tocopherol × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 2 Small Cell Lung Carcinoma 1 Rectal Neoplasms 1 Radiation-induced Injuries in Patients With Rectal Cancer 1 Radiation Injuries 1 Precancerous Conditions 1 Neoplasms, Second Primary 1 Neoplasms 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Fibrosis 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Adenomatous Polyps 1

Interventions

Cyclophosphamide 127 Docetaxel 119 Paclitaxel 108 Trastuzumab 100 Tamoxifen 90 Capecitabine 88 Letrozole 75 Epirubicin 61 Doxorubicin 60 exemestane 55 Anastrozole 53 Fulvestrant 52 Radiotherapy 51 Fluorouracil 49 pertuzumab 32 Gemcitabine 30 Vinorelbine 28 Goserelin 28 Carboplatin 28 Chemotherapy, Adjuvant 26 Zoledronic Acid 24 Methotrexate 24 Lapatinib 23 Bevacizumab 22 eribulin 21 ribociclib 19 palbociclib 19 abemaciclib 17 Aromatase Inhibitors 17 130-nm albumin-bound paclitaxel 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02898376 2018-08-08

FIBROTHERME

Institut de Cancérologie de Lorraine

Phase 3 Unknown

Breast Neoplasms, Fibrosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡